$JNJ (Johnson & Johnson)

$JNJ {{ '2016-01-26T14:49:02+0000' | timeago}} • Webcast

$JNJ's CFO Dominic Caruso said that the company expects transaction currency impacts to negatively impact gross margin by approx. 60-80BP in 2016 compared to last year. On the other hand, operating margin on a pre-tax basis is expected to expand by more than 200 BP in 2016.

$JNJ {{ '2017-07-24T17:21:48+0000' | timeago}} • Announcement

$JNJ said preliminary data from a phase 1/2a clinical trial on an investigational HIV-1 vaccine regimen showed positive results in a sample of 393 healthy volunteers. If the vaccine clears the phase 3 trials, its launch can be expected within a decade. There are currently around 37MM AIDS patients around the world.

$JNJ {{ '2017-07-18T19:50:54+0000' | timeago}} • Webcast

$JNJ expects that the growth acceleration in the back half of 2017 will create some momentum going into 2018, as the majority of growth acceleration in both Hospital Medical Devices and Consumer have to do with new product launches. However, the company said it is not prepared to talk about guidance.

$JNJ {{ '2017-07-18T19:30:46+0000' | timeago}} • Webcast

$JNJ CEO Alex Gorsky said during the conference call, "We remain very optimistic about Pharma in the second half of the year and we continue to see really strong uptake both with DARZALEX and the various multiple myeloma indications earlier utilization."

$JNJ {{ '2017-07-18T18:58:31+0000' | timeago}} • Webcast

$JNJ said it has a pipeline of more than 10 new blockbuster products to launch or file for regulatory approval in the next five years, each with greater than $1Bil in peak year sales potential.

$JNJ {{ '2017-07-18T11:59:48+0000' | timeago}} • Infographic

$JNJ Johnson & Johnson Earnings AlphaGraphics: Q2 2017 highlights

$JNJ {{ '2017-07-18T11:26:59+0000' | timeago}} • Announcement

Medical Devices segment was the top performer for $JNJ in 2Q17, with a growth of 4.9%. While Consumer segment added to this with a 1.7% growth, Pharmaceutical segment edged down 0.2%.

$JNJ {{ '2017-07-18T11:19:55+0000' | timeago}} • Announcement

$JNJ CEO Alex Gorsky said, "Our pharmaceutical pipeline continued its strong momentum with the approval of TREMFYA as well as the submission and approval of several key line extensions. We are optimistic that the investments we are making will accelerate our sales growth in the second half of this year."

$JNJ {{ '2017-07-18T11:14:25+0000' | timeago}} • Announcement

$JNJ, which recently acquired Actelion Ltd for $30Bil, raised its sales guidance for FY17 to $75.8-76.1Bil. Additionally, the New Brunswick, NJ - based company raised its adjusted earnings guidance for the same period to $7.12-7.22 per share.

$JNJ {{ '2017-07-18T11:08:14+0000' | timeago}} • Announcement

Pharmaceutical giant $JNJ reported growth in sales and adjusted EPS in 2Q17. While sales increased 2% to $18.8Bil riding on International sales growth of 2.3%, adjusted EPS stood at $1.83, representing an increase of 3.1%. On a GAAP basis, net earnings were down to $3.8Bil, or $1.40 per share, compared to $4Bil, or $1.43 per share, a year ago.

$JNJ {{ '2017-07-17T15:58:16+0000' | timeago}} • Announcement

$JNJ has declared a cash dividend for 3Q17 of $0.84 per share on its common stock. The dividend is payable on September 12, 2017 to shareholders of record as on August 29, 2017. The ex-dividend date is August 25, 2017.

$JNJ {{ '2017-06-27T15:40:39+0000' | timeago}} • Announcement

DePuy Synthes Products, part of the $JNJ, acquired Innovative Surgical Solutions LLC, doing business as Sentio LLC, a privately-held company based in Wixom, Michigan that markets innovative nerve localization technology for spine surgery. Financial terms of the transaction have not been disclosed.

$JNJ {{ '2017-06-16T19:49:20+0000' | timeago}} • Announcement

Janssen Biotech, a $JNJ company, said FDA has approved immunotherapy Darzalex in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior commonly used therapies. Multiple myeloma is incurable blood cancer that starts in the bone marrow's plasma cells.

$JNJ {{ '2017-06-16T11:31:37+0000' | timeago}} • Announcement

$JNJ expects acquisition of Actelion to add approx $1.3Bil in sales for 2017 and be accretive to 2017 adjusted EPS by approx $0.07. This impact was already included in the company's full-year guidance provided in April. Also, in the first full year after close, $JNJ expects the transaction to add to adjusted EPS by $0.35 to $0.40.

$JNJ {{ '2017-06-16T11:28:17+0000' | timeago}} • Announcement

Upon completion of $JNJ's public tender offer, Actelion has spun off its drug discovery operations assets into a newly created Swiss biopharmaceutical company, Idorsia Ltd. Shares of Idorsia were distributed to Actelion’s shareholders as a stock dividend. A $JNJ unit will initially hold 9.9% of the shares of Idorsia.

$JNJ {{ '2017-06-16T11:23:40+0000' | timeago}} • Announcement

$JNJ has completed the acquisition of Actelion Ltd for about $30Bil in cash. The acquisition was completed through a public tender offer by $JNJ unit Janssen Holding GmbH, to acquire all publicly held shares of Actelion Ltd for $280 per share. Actelion will now become part of the Janssen Pharmaceutical Companies.

$JNJ {{ '2017-06-14T13:47:21+0000' | timeago}} • Announcement

Janssen Pharmaceuticals, a $JNJ company, announced results from the Phase 2b Topaz Trial which demonstrated that treatment with pimodivir significantly decreased viral load over seven days versus placebo, in adult patients with acute, uncomplicated seasonal influenza A.

$MET {{ '2017-06-12T18:19:50+0000' | timeago}} • Announcement

$MET has named Susan Podlogar as EVP and Chief Human Resources Officer, effective July 10. She will be a member of the Executive Group and report to Chairman, President and CEO Steven A. Kandarian. Ms. Podlogar comes to $MET from $JNJ, where she was Global Vice President of Human Resources for the Medical Devices business.

$JNJ {{ '2017-06-09T16:25:32+0000' | timeago}} • Announcement

$JNJ has received all regulatory approvals required to complete the proposed $280 per share acquisition of $ATLN, with the recent receipt of approval from the European Commission.

$JNJ {{ '2017-06-05T11:58:33+0000' | timeago}} • Announcement

Janssen Research & Development, a unit of $JNJ, reported that in phase 3 Latitude clinical trial, its ZYTIGA plus prednisone, in combination with androgen deprivation therapy, showed significant improvement in overall survival in patients with high-risk prostate cancer, as compared to placebo effect.

$JNJ {{ '2017-06-05T11:56:25+0000' | timeago}} • Announcement

Janssen Research & Development, a $JNJ company, announced new data from updated analyses of the pivotal Phase 3 Castor and Pollux clinical studies, demonstrating that Darzalex (daratumumab) combination therapy improved progression-free survival and overall response rate for previously-treated patients with multiple myeloma.

Recent Transcripts

AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm
JNJ (Johnson & Johnson)
Tuesday, July 18 2017 - 12:30pm
ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
CCXI (ChemoCentryx, Inc.)
Wednesday, May 10 2017 - 9:00pm
DRRX (DURECT Corporation)
Wednesday, May 10 2017 - 8:30pm
VCEL (Vericel Corporation)
Wednesday, May 10 2017 - 12:00pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
PTLA (Portola Pharmaceuticals, Inc.)
Monday, May 8 2017 - 8:30pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
ZTS (Zoetis Inc.)
Thursday, May 4 2017 - 12:30pm
ARQL (ArQule Inc.)
Wednesday, May 3 2017 - 1:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, April 28 2017 - 12:30pm
CYTK (Cytokinetics, Incorporated)
Thursday, April 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
AMGN (Amgen Inc)
Wednesday, April 26 2017 - 9:00pm
JNJ (Johnson & Johnson)
Tuesday, April 18 2017 - 12:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, March 14 2017 - 9:00pm
DRRX (DURECT Corporation)
Tuesday, March 14 2017 - 8:30pm
VCEL (Vericel Corporation)
Friday, March 10 2017 - 1:00pm

AlphaGraphics you may like